Endoscopic ultrasound-guided biliary drainage (EUS-BD) is increasingly used as an alternative in patients with biliary obstruction who fail standard endoscopic retrograde cholangiopancreatography (ERCP). The two major endoscopic approach routes for EUS-BD are the transgastric intrahepatic and the transduodenal extrahepatic approaches. Biliary drainage can be achieved by three different methods, transluminal biliary stenting, transpapillary rendezvous technique, and antegrade biliary stenting. Choice of approach route and drainage method depends on individual anatomy, underlying disease, and location of the biliary stricture.
INTRODUCTION

E
NDOSCOPIC RETROGRADE CHOLANGIOPAN-CREATOGRAPHY (ERCP) with transpapillary stent placement is the current gold standard for biliary decompression in patients with malignant biliary obstruction. [1] [2] [3] Although its success rate is generally over 90%, ERCP occasionally fails because of surgically altered anatomy, gastric outlet obstruction, periampullary diverticulum, indwelling duodenal stent and large tumors. [4] [5] [6] Percutaneous transhepatic biliary drainage (PTBD) is the conventionally alternative method in patients who fail ERCP. However, PTBD is associated with high morbidity and can lower patients' quality of life. [7] [8] [9] It may also be difficult to carry out when the intrahepatic bile ducts are not dilated. In cases of failed cannulation in surgically altered anatomies, balloon enteroscopy-assisted ERCP is as an alternative that has shown high technical and clinical success in specialized centers; [10] [11] [12] however, currently, it is not a well-established procedure.
Since first described in 2001, 13 endoscopic ultrasoundguided biliary drainage (EUS-BD) has been increasingly used as an alternative in patients with biliary obstruction who fail standard ERCP. [14] [15] [16] [17] [18] [19] [20] Its potential and efficacy have drawn attention and many articles about EUS-BD have been published in the last decade.
Various endoscopic approaches have been described for EUS-BD, [21] [22] [23] with the two major approach routes being the transgastric intrahepatic and the transduodenal extrahepatic approaches. Three major drainage procedures for EUS-BD have been described: EUS-guided transluminal biliary stenting, EUS-guided rendezvous technique (EUS-RV), and EUS-guided antegrade biliary stenting (EUS-ABS). To date, the optimal strategy of EUS-BD has not been established, with the choice of approach route and drainage procedure depending on the patient's anatomy, underlying disease (benign or malignant), prognosis for survival, and location of the biliary stricture. The aims of this review are to summarize recent clinical findings of EUS-BD topics and to discuss future perspectives.
METHODS
T HE PRESENT REVIEW is based on the results of searches carried out in Medline/PubMed and the Cochrane Library electronic database of studies published between October 2001 and March 2017 using the keywords 'EUS OR endoscopic ultrasound' AND 'biliary drainage'. The initial search identified 549 articles. Of these, 299 articles were deemed relevant to this review based on the screening of their titles. After evaluation of abstracts, complete texts were obtained for potentially relevant articles. A manual recursive search of the reference sections of these articles was carried out to identify other potentially relevant articles. These papers were then reviewed in detail. Finally, in this review, we cite 64 references to papers focusing on EUS-BD that have been published in the last 5 years.
ENDOSCOPIC PROCEDURES OF EUS-BD EUS-guided transluminal drainage
EUS-guided choledochoduodenostomy E US-GUIDED CHOLEDOCHODUODENOSTOMY (EUS-CDS) (Fig. 1) is one method of EUS-guided transluminal stenting between the duodenal bulb (D1) and the extrahepatic bile duct, which was first described in 2001. 13 Patients with distal bile duct obstruction and normal gastrointestinal anatomy may be candidates for this procedure.
Puncture and guidewire manipulation. The extrahepatic bile duct can be visualized through the D1 on EUS. It is important to identify the cystic duct to prevent incorrect puncture. The bile duct is usually punctured with a 19-gauge (G) needle used for fine-needle aspiration (FNA). During the EUS-CDS procedure, the puncture angle must be adjusted so that the guidewire easily passes through toward the hilum. Bile is aspirated after puncture, and contrast medium is injected to obtain a cholangiogram. Thereafter, a guidewire is advanced into the bile duct and manipulated into the desired position.
Fistulous tract dilation. The fistulous tract is dilated using a bougie, balloon, or cautery dilator while maintaining the guidewire in place. Recently, a fine-gauge balloon dilator has become available. 24, 25 The tip is tapered to less than 3 Fr in diameter and is coaxial with a 0.025-inch guidewire. After puncturing the bile duct with a 19-G FNA needle, the balloon catheter can be easily inserted without any dilation devices. A 4-mm balloon catheter is usually used to insert the stent device.
Stent deployment.
A stent is deployed through the dilated fistulous tract between the D1 and the extrahepatic bile duct. Most studies to date have used self-expandable metal stents. [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] A fully or partially covered tubular stent is often selected for EUS-CDS. 26 Metal stents longer than 4 cm have been used to prevent internal stent migration. 26, 27 A recent study described the performance of EUS-CDS in 57 patients using a novel lumen-apposing metal stent (LAMS), resulting in high technical and clinical success rates. 28 The new LAMS has multiple advantages including avoidance of puncture and guidewire insertion, especially within the context of the Hot-Axios system (XLumina Axios, Boston Scientific, Natick, MA, USA). 28 
EUS-guided hepaticogastrostomy
EUS-guided hepaticogastrostomy (EUS-HGS) (Fig. 2) is another EUS-guided transluminal stenting procedure, involving transluminal stenting between the stomach and the left intrahepatic bile duct. 29 The presence of a dilated left intrahepatic bile duct is essential for this procedure. This procedure is thought to have wider applications than the EUS-CDS procedure. For example, although EUS-CDS is contraindicated in patients with surgically altered anatomy (e.g. Roux-en-Y or Whipple reconstruction) or duodenal obstruction as a result of tumor invasion, EUS-HGS can be carried out in these patients, as well as in patients with distal bile duct obstruction. For hilar biliary obstruction, EUS-HGS is indicated as a rescue procedure in biliary reinterventions. 30, 31 Massive ascites between the stomach and liver and unresectable gastric cancer are considered contraindications for EUS-HGS. 32 Puncture and guidewire manipulation. The left intrahepatic bile duct can be well visualized through the gastric body. When a gastric body puncture is carried out, the intrahepatic bile duct of segment 3 (B3) is usually selected. The intrahepatic bile duct of segment 2 can be accessed through the esophagus, which may cause severe adverse events, such as mediastinitis or pneumomediastinum. 32 The angle of bile duct puncture is important for advancing the guidewire toward the hepatic hilum. Bile ducts that run from the upper left to the lower right on EUS images are considered the ideal puncture position. A bile duct diameter >5 mm and a 1-3-cm linear distance from the mural wall to the punctured bile duct wall on EUS may be suitable for successful EUS- HGS. 33 When sludge or debris in the bile duct makes visualizing the B3 difficult, contrast-enhanced EUS may be useful to clearly visualize the B3. 34 Fistulous tract dilation. As with EUS-CDS, a 0.025-or 0.035-inch guidewire is inserted through the 19-G FNA needle and manipulated to advance it toward the hepatic hilum. After the guidewire is advanced into the biliary system, the fistulous tract is dilated using a bougie, balloon, or cautery dilator, as described for EUS-CDS. Insertion of the stent device requires dilation of the bile duct and gastric wall.
Stent deployment. A stent is deployed through the dilated fistulous tract between the gastric body and the B3. Recent studies have mainly used fully covered or partially covered self-expandable metal stents. 32, 35 Inward stent migration is a serious adverse event, especially soon after the procedure. 36, 37 A recent study reported that stent length ≥3 cm in the gastrointestinal lumen can prevent stent migration after deployment. Furthermore, a longer luminal length may be related to long-term stent patency. Therefore, metal stents longer than 10 cm may be suitable. 35, 38 A novel stent deployment maneuver has been reported to secure the deployed metal stent in a stable position and prevent stent migration. 39 Specifically, half the metal stent was deployed within the bile duct under echoendoscopic and fluoroscopic guidance, and the remaining portion of the metal stent was deployed within the echoendoscope channel under fluoroscopic guidance. Subsequently, the echoendoscope was pulled out gently and the stent was left in the HGS site. 39 
EUS-guided rendezvous technique
In the EUS-guided rendezvous technique (EUS-RV) (Fig. 3) , first described in 2004, 40 the bile duct is accessed under EUS guidance with the creation of a temporary fistula, Digestive
followed by guidewire advancement across the ampulla into the duodenum. Initially, conventional transpapillary biliary cannulation under guidance of the duodenoscope is attempted using the EUS-placed guidewire. EUS-RV is indicated in patients who fail ERCP but have endoscopic access to the ampulla or anastomosis site. Unlike transluminal stenting, EUS-RV preserves the anatomical integrity of the biliary tree and avoids creation of a permanent fistula. Therefore, this procedure is particularly indicated for patients with resectable malignant biliary obstruction or benign biliary disorders (e.g. stone disease).
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Puncture and guidewire manipulation. The EUS-RV technique can be carried out by three different approaches: intrahepatic bile duct approach from the stomach, extrahepatic bile duct approach from the D1, and extrahepatic bile duct approach from the second portion of the duodenum (D2). The bile duct is accessed using a 19-G or 22-G FNA needle. After bile is aspirated, contrast is injected. Following cholangiography, a long guidewire is passed through the access needle into the bile duct and duodenum through the stricture and ampulla. Guidewire manipulation is the most challenging technical aspect of this procedure, as well as being key to the success of EUS-RV. 21, 41, 42 A hydrophilic guidewire was shown to be useful for passing the ampulla. 43 Recent studies showed that the extrahepatic bile duct approach from the D2 minimized the challenges associated with guidewire manipulation and could improve the success rate of EUS-RV. However, this approach was not always feasible because of instability of the scope position. 44, 45 Transpapillary biliary cannulation. After the guidewire is manually manipulated to cross the ampulla and is coiled within the duodenum, the needle and echoendoscope are withdrawn, leaving the guidewire in place. A duodenoscope is inserted alongside the guidewire, and the biliary tree is deeply cannulated with an ERCP catheter, using the EUSplaced guidewire to locate the biliary opening. Successful access to the bile duct allows completion of conventional ERCP in the usual method.
EUS-guided antegrade biliary stenting
EUS-guided antegrade biliary stenting (EUS-ABS) (Fig. 4) is a recently developed variation of EUS-BD first described in 2008. 46 In EUS-ABS, a biliary stent is deployed in an antegrade method through the intrahepatic bile duct accessed through the gastrointestinal lumen under EUS guidance. This technique is suitable in patients with an endoscopically inaccessible ampulla resulting from surgically altered anatomy or duodenal obstruction. 47 Puncture and guidewire manipulation. In EUS-ABS, the left intrahepatic bile duct is accessed from the gastric body or small intestine, with the creation of a temporary fistula between the gastrointestinal lumen and the intrahepatic bile duct. Similar to EUS-HGS, the left intrahepatic bile duct is punctured under EUS guidance, and a guidewire is inserted deeply into the biliary tree and is manipulated into the gastrointestinal lumen across the ampulla or anastomosis site.
Fistulous tract dilation. In EUS-ABS, a fistulous tract is temporarily created and unsealed after stent placement, with the minimal fistulous tract dilation reducing the risk of bile leakage. Recently developed, commercially available uncovered metal stents with a fine-gauge (5.7 or 6 Fr) stent delivery system can be deployed without fistulous tract dilation using a bougie or balloon dilator if an ERCP catheter can pass through the fistula. [47] [48] [49] Use of these stents in EUS-ABS may minimize bile leakage.
Stent deployment. A metal or plastic stent is inserted through the left intrahepatic bile duct into the malignant stricture site and deployed to cover the stricture in an antegrade fashion. Metal stent deployment over the ampulla or anastomosis may reduce the risk of bile peritonitis by reducing the internal pressure of the biliary system. 47 The ideal location of the stent, however, whether covering or above the ampulla, is currently unclear.
OUTCOMES OF EUS-BD
Technical and clinical success T HREE RECENT META-ANALYSES reported cumulative technical success rates ranging from 90% to 94.7%. 14, 15, 17 According to Attasaranya et al., the failure rate was 38% during the first 3 years of EUS-BD, but only 11% during the last 2 years; thus a learning curve period is likely required to improve technical skills of the operators. 50 A learning curve effect was also suggested by the cumulative experience of 101 procedures carried out at a single center. 51 That study found that there were five procedure-related deaths among the first 50 patients during the first 5 years, but only one procedure-related death among the last 51 patients during the last 2 years. 51 A retrospective multicenter survey of 125 patients in Spain who underwent EUS-BD found that the technical success rates of EUS-BD carried out by two endoscopists and by one endoscopist were 80% and 57%, respectively, 52 suggesting that the skill of the assistant who manipulates guidewires and releases stents is of great importance to the success of EUS-BD.
A recent systematic analysis found no significant differences in technical success rates, clinical success rates, and adverse event rates between patients who underwent the procedure using the transgastric through intrahepatic and transduodenal through extrahepatic approaches. 15 A prospective single-center study found that the clinical success rate tended to be higher for EUS-HGS than for EUS-CDS. 53 A comparison of EUS-CDS and EUG-HGS reported stent dysfunction rates of 21% and 32%, respectively, and 3-month stent patency rates of 80% and 51%, respectively. 54 The choice of drainage route when both are possible remains unclear. Prospective randomized comparative studies are required to assess the relative safety and efficacy of these approaches.
Analysis of drainage methods found that the technical success rate of EUS-RV was 81%, 21 lower than that of transluminal drainage. The EUS-RV procedure, however, is relatively complicated as it requires scope exchange and skillful guidewire manipulation.
EUS-ABS, but not EUS-RV, can be carried out in patients with an endoscopically inaccessible ampulla or anastomosis site, although both EUS-ABS and EUS-RV avoid creation of a permanent fistula. A recent systematic analysis showed that the technical success rate of EUS-ABS was 91.3%, 15 similar to that of EUS-guided transluminal drainage. However, the numbers of included patients were limited.
No universal consensus has yet been reached on the optimal first-line approach route or method. Recently, a novel individualized algorithm based on patient anatomy was found to maximize efficacy and safety. 55 According to this algorithm, an intrahepatic approach with ABS, or HGS if ABS was not feasible, should be used for patients with a dilated intrahepatic bile duct. By contrast, an extrahepatic bile duct approach with RV, or transluminal stenting if RV was not feasible, should be used for patients with a nondilated intrahepatic bile duct. If an intrahepatic approach was attempted but unsuccessful, the patient should be converted to an extrahepatic approach. If RV or ABS is being considered, an intrahepatic approach is optimal, theoretically because use of the intrahepatic approach entails puncturing the needle downstream of the peripheral intrahepatic bile duct, with subsequent guidewire manipulation being relatively easy and allowing subsequent RV and ABS. 56 EUS-guided gallbladder drainage (EUS-GBD) may be an alternative route for decompression of the biliary tree in patients with malignant biliary obstruction. For example, evaluation of 12 patients who underwent EUS-GBD for malignant biliary obstruction after unsuccessful ERCP as well as EUS-BD resulted in high technical and clinical success rates with few adverse events. 57 These studies suggest that if it is difficult to carry out EUS-BD by the initial plan, alternative planning, including changing the approach route or drainage procedure, may be successful. Further prospective studies comparing these procedures are needed to establish an optimal treatment algorithm for EUS-BD. Digestive Endoscopy 2018; 30: 38-47 Recent advances in EUS-BD 43
Adverse events
Recent systematic analyses of EUS-BD found that the cumulative adverse event rates ranged from 16.5% to 23.3%, 14, 15, 17 higher than that for ERCP. 58 The most frequent complications of EUS-BD included bleeding, bile leakage, pneumoperitoneum, stent migration, cholangitis, abdominal pain, and peritonitis. 14, 15, 17 Most adverse events could be treated conservatively. By contrast, stent migration into the peritoneal cavity is considered a serious adverse event of EUS-HGS and can even be fatal. 36, 37 The adverse events associated with EUS-BD are related to approach route, types of device used, state and extent of disease, and experience of the operator. Most adverse events are associated with beginners in this field, with lower adverse event rates reported by experienced centers. 51, 52 Therefore, experts recommend that someone new to this procedure be supervised on at least the first 20 patients. 19 A systematic review of 20 studies reported that adverse event rates were higher for the intrahepatic (18%) than for the extrahepatic (14%) approach. 59 Comparisons of drainage methods showed adverse event rates lower for RV (11%, including 3.4% with acute pancreatitis) than for transluminal drainage (21%). 59 Bile leakage was more frequently observed in patients who underwent plastic (11%) than covered metal stent (4%) deployment. 54 Analysis of risk factors for adverse events showed that use of plastic stents and non-coaxial electrocautery for fistula dilation were independently associated with an increased risk of adverse events. 59 At present, few endoscopic tools and devices are available for EUS-BD, with most devices used adapted from equipment used for ERCP, resulting in device-related shortcomings. New comfortable stenting devices that prevent complications related to EUS-BD are therefore needed. Recent studies have described the development of specially designed and modified stents for EUS-BD, including lumen-apposing metal stents (LAMS); 28, [60] [61] [62] hybrid metal stents consisting of uncovered proximal portions and covered distal portions; 27, 63 hook stents (laser-cut metal stents with anchoring hooks) 64 ; and 8-Fr single-pigtail plastic stents with four flanges dedicated for EUS-HGS. 65 These new devices are expected to reduce rates of stent-related adverse events. 66 Two prospective randomized studies comparing EUS-BD and PTBD after failed ERCP reported that these methods have similar levels of efficacy, based on technical and clinical success rates and quality of life. 69, 70 In one study, EUS-BD resulted in lower rates of procedurerelated adverse events and unscheduled reinterventions. 70 A systematic review and meta-analysis comparing EUS-BD and PTBD in 483 patients reported no difference in technical success rates, but found that EUS-BD was associated with higher clinical success rates and lower post-procedure adverse event and reintervention rates when compared with PTBD. 71 These findings suggest that EUS-BD is a safe and good alternative to PTBD after failed ERCP if adequate expertise in advanced endoscopy is available.
COMPARISON WITH TRADITIONAL MEANS
EUS-BD versus ERCP
EUS-BD is currently positioned as a rescue biliary drainage option after failed ERCP, not as a first-line therapy. One study at a tertiary care center found that EUS-BD was required by only three (0.6%) of 524 patients with a native papilla undergoing therapeutic ERCP, concluding that EUS-BD should not replace good ERCP techniques. 72 A prospective study of 18 patients who underwent EUS-CDS as primary biliary intervention for malignant biliary obstruction after unsuccessful ERCP found that the technical and clinical success rates were 94% and 100%, respectively. 73 A retrospective comparative cohort study comparing the clinical efficacy and safety of EUS-CDS and ERCP as first-line treatment for distal malignant biliary obstruction in 82 patients (26 EUS-CDS, 56 ERCP) found that mean procedure time was significantly shorter with EUS-CDS than with ERCP, although their clinical success and adverse event rates were similar. 74 Similar results were observed in another retrospective study comparing EUS-BD and ERCP. 75 Another retrospective study in an academic center in Japan reported that the technical success and adverse event rates of primary EUS-BD without ERCP failure were comparable to those of rescue EUS-BD with ERCP failure. 76 The high technical and clinical success rates of EUS-BD suggest that, in the near future, this method could be a primary biliary drainage option in patients with ampulla covered by a duodenal stent or with surgically altered anatomy. Nevertheless, standardizing the procedure and prospective comparative multicenter trials are still needed.
